Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Ron Dior who wrote (1070)	5/21/1998 12:01:00 AM
From: David Winkler	Read Replies (2) \| Respond to of 2135

More reasons for holding over $30 I would like to present another view as to why ENMD is holding over 30. Every generation there is an event or discovery that changes the course of history . This century three medical advances come to mind, penicillin, the polio vaccine and the ability to successfully transplant organs. There may be others. Entremed is working in two areas that MAY represent such a discovery. They have two chances to swing for the fences. If either one works anywhere near expectations then this is a billion dollar plus company ($80-120) If both work then double or triple that. Will they work? Who knows but the theory is sound in both areas. If it were a sure thing the stock would be $200 not $33. If they strike out the stock will end with loud thud. MEDX has been hyped on this thread over and over again. They have a different approach which likely will be beneficial as well. They however depend on the expression of structures on the surface of the tumors. The tumor may be able to develop resistance by down regulating expression of the structures. One of the benefits of Angio/Endo is that no resistance is seen, nor should it be since the compound works on new blood vessels, not on the tumors themselves. I think we are hearing contradictory voices from the scientific community. Dr. Watson's "retraction" was not really a retraction. He reiterated that this was a (the?) most exciting discovery in cancer research. We are clearly early in the game and the enthusiastic reaction of the investment community and patient population needed to be restrained. IHP is the second area. If you do not know about IHP and you are short (or long) you should educate yourself. Try ENMD's web site. entremed.com